Logo image of COYA

COYA THERAPEUTICS INC (COYA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:COYA - US22407B1089 - Common Stock

5.74 USD
-0.17 (-2.88%)
Last: 12/16/2025, 2:17:53 PM
Fundamental Rating

3

Taking everything into account, COYA scores 3 out of 10 in our fundamental rating. COYA was compared to 529 industry peers in the Biotechnology industry. While COYA has a great health rating, there are worries on its profitability. COYA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

COYA had negative earnings in the past year.
In the past year COYA has reported a negative cash flow from operations.
COYA had negative earnings in each of the past 5 years.
In the past 5 years COYA always reported negative operating cash flow.
COYA Yearly Net Income VS EBIT VS OCF VS FCFCOYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -57.53%, COYA perfoms like the industry average, outperforming 43.67% of the companies in the same industry.
The Return On Equity of COYA (-67.56%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -57.53%
ROE -67.56%
ROIC N/A
ROA(3y)-66.21%
ROA(5y)-61.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COYA Yearly ROA, ROE, ROICCOYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for COYA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COYA Yearly Profit, Operating, Gross MarginsCOYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

8

2. Health

2.1 Basic Checks

COYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for COYA has been increased compared to 1 year ago.
COYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COYA Yearly Shares OutstandingCOYA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
COYA Yearly Total Debt VS Total AssetsCOYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 12.25 indicates that COYA is not in any danger for bankruptcy at the moment.
The Altman-Z score of COYA (12.25) is better than 83.93% of its industry peers.
There is no outstanding debt for COYA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.25
ROIC/WACCN/A
WACC8.83%
COYA Yearly LT Debt VS Equity VS FCFCOYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

COYA has a Current Ratio of 8.73. This indicates that COYA is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.73, COYA is doing good in the industry, outperforming 77.13% of the companies in the same industry.
COYA has a Quick Ratio of 8.73. This indicates that COYA is financially healthy and has no problem in meeting its short term obligations.
COYA has a Quick ratio of 8.73. This is in the better half of the industry: COYA outperforms 77.13% of its industry peers.
Industry RankSector Rank
Current Ratio 8.73
Quick Ratio 8.73
COYA Yearly Current Assets VS Current LiabilitesCOYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

COYA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -111.54%.
The Revenue for COYA has decreased by -58.26% in the past year. This is quite bad
EPS 1Y (TTM)-111.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-58.26%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.57% on average over the next years. This is quite good.
COYA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.26% yearly.
EPS Next Y-23.66%
EPS Next 2Y-24.89%
EPS Next 3Y-9.44%
EPS Next 5Y10.57%
Revenue Next Year82.55%
Revenue Next 2Y-83.34%
Revenue Next 3Y32.27%
Revenue Next 5Y28.26%

3.3 Evolution

COYA Yearly Revenue VS EstimatesCOYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
COYA Yearly EPS VS EstimatesCOYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

COYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COYA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COYA Price Earnings VS Forward Price EarningsCOYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COYA Per share dataCOYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

COYA's earnings are expected to decrease with -9.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.89%
EPS Next 3Y-9.44%

More info and screens

0

5. Dividend

5.1 Amount

COYA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

COYA THERAPEUTICS INC

NASDAQ:COYA (12/16/2025, 2:17:53 PM)

5.74

-0.17 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-16 2026-03-16/bmo
Inst Owners18.8%
Inst Owner Change6%
Ins Owners1.2%
Ins Owner Change1.69%
Market Cap120.08M
Revenue(TTM)3.99M
Net Income(TTM)-18.43M
Analysts83.08
Price Target16.39 (185.54%)
Short Float %2.52%
Short Ratio2.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.77%
Min EPS beat(2)10.16%
Max EPS beat(2)53.37%
EPS beat(4)3
Avg EPS beat(4)-5.14%
Min EPS beat(4)-121.22%
Max EPS beat(4)53.37%
EPS beat(8)5
Avg EPS beat(8)-2.98%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-42.52%
Min Revenue beat(2)-79.47%
Max Revenue beat(2)-5.56%
Revenue beat(4)0
Avg Revenue beat(4)-68.14%
Min Revenue beat(4)-97.13%
Max Revenue beat(4)-5.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.88%
PT rev (3m)-3.43%
EPS NQ rev (1m)41.3%
EPS NQ rev (3m)43.27%
EPS NY rev (1m)22.41%
EPS NY rev (3m)22.63%
Revenue NQ rev (1m)1331.22%
Revenue NQ rev (3m)1331.22%
Revenue NY rev (1m)33.99%
Revenue NY rev (3m)33.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.11
P/FCF N/A
P/OCF N/A
P/B 4.4
P/tB 4.4
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.19
BVpS1.3
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -57.53%
ROE -67.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.21%
ROA(5y)-61.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.73
Quick Ratio 8.73
Altman-Z 12.25
F-Score2
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-111.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-23.66%
EPS Next 2Y-24.89%
EPS Next 3Y-9.44%
EPS Next 5Y10.57%
Revenue 1Y (TTM)-58.26%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year82.55%
Revenue Next 2Y-83.34%
Revenue Next 3Y32.27%
Revenue Next 5Y28.26%
EBIT growth 1Y-80.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.7%
OCF growth 3YN/A
OCF growth 5YN/A

COYA THERAPEUTICS INC / COYA FAQ

What is the fundamental rating for COYA stock?

ChartMill assigns a fundamental rating of 3 / 10 to COYA.


What is the valuation status for COYA stock?

ChartMill assigns a valuation rating of 0 / 10 to COYA THERAPEUTICS INC (COYA). This can be considered as Overvalued.


What is the profitability of COYA stock?

COYA THERAPEUTICS INC (COYA) has a profitability rating of 1 / 10.


What is the expected EPS growth for COYA THERAPEUTICS INC (COYA) stock?

The Earnings per Share (EPS) of COYA THERAPEUTICS INC (COYA) is expected to decline by -23.66% in the next year.